Probiotics administration following sleeve gastrectomy surgery: A randomized double-blind trial

International Journal of Obesity

Volumn 42, Issue 2, 2018, Pages 147-155

  Sherf Dagan, S ^a,b,c   Zelber Sagi, S ^a,d   Zilberman Schapira, G ^e   Webb, M ^a   Buch, A ^a,c   Keidar, A ^b,f   Raziel, A ^b   Sakran, N ^b,g   Goitein, D ^b,c,h   Goldenberg, N ^b   Mahdi, J A ^e,f   Pevsner Fischer, M ^e   Zmora, N ^a,c,e   Dori Bachash, M ^e   Segal, E ^e   Elinav, E ^e   Shibolet, O ^a,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b ASSUTA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF HAIFA   (Israel)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g HAEMEK MEDICAL CENTER   (Israel)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIO 25; C REACTIVE PROTEIN; CYTOKERATIN 18; LEPTIN; LIVER ENZYME; METFORMIN; PLACEBO; PROBIOTIC AGENT;

ABDOMINAL RADIOGRAPHY; ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL OUTCOME; CONTROLLED STUDY; DATA COLLECTION METHOD; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOGRAPHY; FAT CONTENT; FATTY LIVER; FECES; FECES MICROFLORA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LAPAROSCOPIC SLEEVE GASTRECTOMY; LIVER; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLIC PARAMETERS; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK REDUCTION; SHEAR WAVE ELASTOGRAPHY; SIDE EFFECT; SURGICAL PATIENT; TREATMENT DURATION; BARIATRIC SURGERY; DIAGNOSTIC IMAGING; DIET THERAPY; ELASTOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; BARIATRIC SURGERY; DOUBLE-BLIND METHOD; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POSTOPERATIVE PERIOD; PROBIOTICS; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 85041652186     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2017.210     Document Type: Article

References (38)

1. Hannah Jr WN, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis 2016; 20: 339-350.
2. Bower G, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A et al. Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg 2015; 25: 2280-2289.
3. Lee WJ, Almulaifi A. Recent advances in bariatric/metabolic surgery: Appraisal of clinical evidence. J Biomed Res 2015; 29: 98-104.
4. Benaiges D, Mas-Lorenzo A, Goday A, Ramon JM, Chillaron JJ, Pedro-Botet J et al. Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure World J Gastroenterol 2015; 21: 11804-11814.
5. Sweeney TE, Morton JM. Metabolic surgery: Action via hormonal milieu changes, changes in bile acids or gut microbiota A summary of the literature. Best Pract Res Clin Gastroenterol 2014; 28: 727-740.
6. Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2013; 13: 514-522.
7. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049-3057.
8. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009; 106: 2365-2370.
9. Kong LC, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013; 98: 16-24.
10. Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Konigsrainer A et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int 2015; 2015: 806248.
11. Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med 2016; 8: 67.
12. Murphy R, Tsai P, Jullig M, Liu A, Plank L, Booth M. Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg 2017; 27: 917-925.
13. Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: A prospective randomized trial. J Gastrointest Surg 2009; 13: 1198-1204.
14. Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab 2016; 5: 782-794.
15. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543.
16. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276-1285.
17. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 2014; 97: 7386-7393.
18. Fernandes R, Beserra BT, Mocellin MC, Kuntz MG, da Rosa JS, de Miranda RC et al. Effects of prebiotic and synbiotic supplementation on inflammatory markers and anthropometric indices after Roux-en-Y gastric bypass: A randomized, triple-blind, placebo-controlled pilot study. J Clin Gastroenterol 2016; 50: 208-217.
19. Chen JC, Lee WJ, Tsou JJ, Liu TP, Tsai PL. Effect of probiotics on postoperative quality of gastric bypass surgeries: A prospective randomized trial. Surg Obes Relat Dis 2016; 12: 57-61.
20. Doig GS, Simpson F. Randomization and allocation concealment: A practical guide for researchers. J Crit Care 2005; 20: 187-191; discussion 91-93.
21. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
22. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1: 100-107.
23. Keinan-Boker L, Noyman N, Chinich A, Green MS, Nitzan-Kaluski D. Overweight and obesity prevalence in Israel: findings of the first national health and nutrition survey (MABAT). Isr Med Assoc J 2005; 7: 219-223.
24. Bentur N, King Y. The challenge of validating SF-12 for its use with communitydwelling elderly in Israel. Qual Life Res 2010; 19: 91-95.
25. Gore R. Diffuse liver disease. In: Gore R, Levine M, Laufer I (eds). Editor Textbook of Gastrointestinal Radiology. Saunders: Philadelphia, PA, USA, 1994; pp 1968-2017.
26. Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014; 20: 4382-4392.
27. Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909-914.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
29. Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L et al. Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. J Hepatol 2013; 58: 928-935.
30. Toolabi K, Arefanian S, Golzarand M, Arefanian H. Effects of laparoscopic Roux-en-Y gastric bypass (LRYGB) on weight loss and biomarker parameters in morbidly obese patients: A 12-month follow-up. Obes Surg 2011; 21: 1834-1842.
31. Mirrakhimov AE, Lunegova OS, Kerimkulova AS, Moldokeeva CB, Nabiev MP, Mirrakhimov EM. Cut off values for abdominal obesity as a criterion of metabolic syndrome in an ethnic Kyrgyz population (Central Asian region). Cardiovasc Diabetol 2012; 11: 16.
32. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A et al. Personalized nutrition by prediction of glycemic responses. Cell 2015; 163: 1079-1094.
33. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 262-266.
34. Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015; 22: 228-238.
35. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013; 19: 6911-6918.
36. Aron-Wisnewsky J, Dore J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 2012; 9: 590-598.
37. Tanaka Y, Takami K, Nishijima T, Aoki R, Mawatari T, Ikeda T. Short-and long-term dynamics in the intestinal microbiota following ingestion of Bifidobacterium animalis subsp. lactis GCL2505. Biosci Microbiota Food Health 2015; 34: 77-85.
38. Mancini M, Prinster A, Annuzzi G, Liuzzi R, Giacco R, Medagli C et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism 2009; 58: 1724-1730.